Rain Oncology (RAIN) (formerly Rain Therapeutics) is a late-stage oncology company that is focused on developing therapies that target oncogenic drivers to genetically select patients. RAIN was rated a new fundamental buy here on Thursday by a sell-side firm with a $16 price target. Let's check out RAIN's charts and indicators to see where its shares may go from here.
More from Stocks
We've seen some denial about the level of Fed hawkishness, and the action now reflects a more realistic view of the economic situation.
These companies managed to produce solid results in a difficult fourth quarter.